Biosimilars up - but not yet running
This article was originally published in Scrip
The EU framework for biosimilar medicines is working and delivering products, but they are not penetrating the market as quickly as generics firms had hoped. This was one of the key messages to emerge from a recent conference in London organised by the European Generic medicines Association (EGA).
You may also be interested in...
With the number of COVID-19 cases continuing to rise across Europe, the European Commission executive has published a set of actions to be taken at EU and national level to ensure future vaccines are allocated fairly, targeted at priority populations, and labeled in a way that increases production capacity, reduces transport costs and improves distribution.
A consultation on plans for the early availability of coronavirus vaccines drew almost 192,000 responses, including a number of concerns to which the government has now responded.
The health technology assessment bodies for England and Scotland have this week issued positive recommendations on the funding of several innovative new medicines on the National Health Service, including products for myeloma, kidney cancer and multiple sclerosis.